Cisplatin vs Paclitaxel for Triple Negative Breast Cancer
Status:
Active, not recruiting
Trial end date:
2023-06-01
Target enrollment:
Participant gender:
Summary
This is a phase II study randomizing patients with stage I with T1 > 1.5 cm, stage II or III
triple negative breast cancer (TNBC) to preoperative cisplatin versus paclitaxel. The study
is designed to evaluate the ability of the Homologous Recombination Deficiency (HRD) assay to
predict pathologic response to preoperative chemotherapy.
Phase:
Phase 2
Details
Lead Sponsor:
Dana-Farber Cancer Institute
Collaborators:
Myriad Genetics, Inc. Translational Breast Cancer Research Consortium